Accordingly, quantification of IHC showed a reduced percentage of Ki67 positive cells and increased cleaved caspase 3 staining in setanaxib group, while the opposite effects were observed in galunisertib-treated tumours (Fig. 8c). Here, MKI67 is linked to neoplasm.